1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
GeneOne Life Science, Inc.

GeneOne Life Science, Inc.

011000.KS
GeneOne Life Science, Inc.KR flagKorea Exchange
1,084.00
KRW
+11.00
- -
19.66BMarket Cap
GeneOne Life Science, Inc.
011000.KS
(Korea Exchange)

Recent

price

1,084.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1,185.44
1,319.7
846.73
762.96
4,493.78
851.25
937.66
790.17
848.58
1,131.47
567.53
521.27
628.29
516.96
449.66
279.55
200.85
Revenue per Share
-386.59
-234.9
-387.74
-308.88
-1,184.66
42.43
-466.24
-690.08
-294.41
-209.02
-255.01
-214
-492
-1,000
-611
-629
-532.51
Basic EPS, GAAP
-415.75
-153.16
-277.69
-94.99
-893.98
-40.38
-433.97
-129.49
-270
-117.41
-441.49
-1,176.78
-896.57
-352.29
-244.53
-201.37
-186.3
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
32.01
241.97
-2.05
-49.83
230.51
290.05
-65.68
-615.66
-803.87
-1,107.01
-503.16
-279.65
-766.09
-1,771.38
-2,326.46
-2,807.41
-2,678.47
Book Value per Share
1,082.96
1,193.85
857.14
657.97
5,450.21
1,053.53
946.25
946.71
714.8
644.22
1,337.72
2,772.86
2,333.06
1,428.65
1,075.24
493.6
597.51
Tangible Book Value per Share
20
21
23
27
5
33
33
34
40
36
73
74
78
78
79
82
85
Basic Weighted Avg Shares
23,282
27,737
19,410
20,657
24,625
28,365
31,371
27,171
34,293
41,241
41,503
38,700
48,718
40,203
35,720
23,045
17,122
Sales/Revenue/Turnover
-7.56
-16.43
-43.26
-30.55
-26.1
-12.79
-44.61
-91.5
-32.83
-19.9
-44.48
-70.86
-82.27
-120.31
-134.93
-211.64
-245.59
Operating Margin (%)
2,153
2,349
2,028
1,894
1,636
1,124
1,133
1,104
1,294
3,420
4,021
4,650
5,424
12,776
17,961
18,196
13,826
Depreciation Expense
-7,592
-4,937
-8,888
-8,363
-6,492
1,414
-15,599
-23,730
-11,898
-7,619
-18,648
-15,888
-38,150
-77,768
-48,537
-51,851
-45,396
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-32.61
-17.8
-45.79
-40.48
-26.36
4.98
-49.72
-87.33
-34.69
-18.47
-44.93
-41.05
-78.31
-193.44
-135.88
-225
-265.13
Profit Margin (%)
10,424
16,768
13,952
13,090
25,164
28,591
24,233
26,085
19,371
13,943
72,055
99,875
39,227
11,705
-13,870
-34,369
-29,253
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
2,013
794
7,103
5,509
12,358
20,853
22,284
23,503
LT Debt
32,036
33,794
26,741
23,711
34,731
39,439
35,852
36,540
29,410
24,060
98,509
206,507
181,471
111,489
85,605
40,898
51,155
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-172.8
- -
- -
- -
25.87
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
10,474
10,674
10,649
LT Borrowings
17,043
20,018
21,113
LT Finance Leases
2,868
2,266
2,390
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
85
85
91
Market Capitalization
916,471
806,906
390,437

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
23,843
19,437
24,670
Cash, Cash Equivalents & STI
2,707
1,735
5,724
Accounts Receivable, Net
3,976
1,742
1,978
Inventories
15,401
13,422
13,121
Total Current Liabilities
47,976
53,806
53,922
Payables & Accruals
- -
- -
- -
ST Debt
10,474
10,674
10,649
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
24.81%
-3.3%
-52.22%
Free Cash Flow
169.43%
9.19%
-14.54%
Net Income, GAAP
-89.39%
39.68%
6.83%
Sales/Revenue/Turnover
-0.07%
-9%
-35.49%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,032
9,290
8,893
10,505
35,720
2025
8,504
6,813
5,076
2,652
23,045
2026
2,581
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-121
-39
-255
- -
-611
2025
-111
-186.39
-135.16
- -
-629
2026
-27
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
BioLight Life Sciences Ltd. (BOLT.TA)
Leap Therapeutics, Inc. (LPTX)
Mirum Pharmaceuticals, Inc. (MIRM)
BRIM Biotechnology, Inc. (6885.TWO)
Allakos Inc. (ALLK)
Immatics N.V. (IMTX)
Business
GeneOne Life Science, Inc. (011000.KS) operates as a biopharmaceutical company focused on the research, development, and contract manufacturing of nucleic acid-based biomedicines, including DNA and mRNA vaccines, gene therapies, plasmid-encoded monoclonal antibodies, recombinant proteins, and small molecule immunotherapeutics; its pipeline features GLS-1027 in Phase I for nephropathy and inflammatory diseases, GLS-1200 in Phase II for rhinosinusitis and COVID-19, GLS-7000 for breast cancer, GLS-7100 for hemophilia A, GLS-8000 for chronic hepatitis B prevention, and GLS-8100 for rheumatoid arthritis, alongside cGMP production of DNA plasmids and mRNA through subsidiary VGXI, Inc. in The Woodlands, Texas. The company targets emerging infectious diseases such as Zika, Lassa fever, Ebola, HIV, MERS, and COVID-19, as well as cancers including HPV-related, glioblastoma multiforme, and prostate cancer, serving global academic and commercial partners in the United States, Korea, Canada, Europe, and resource-challenged regions. Founded in 1976 and headquartered at Parc.1 NH Finance Tower, 20th Floor, Seoul, South Korea, with financial and R&D operations in Seoul and global clinical development in Blue Bell, Pennsylvania, USA, GeneOne Life Science recently expects to receive KRW 5 billion in funding from Shared Growth Fund No. 1 via series 6 unregistered unsecured private convertible bonds issued on October 29, 2025, with payment on November 4, 2025; announced a KRW 10 billion stock sale in September 2025; and received KRW 3.6 billion in funding in March 2024, reflecting ongoing capital raises to support pipeline advancement and manufacturing expansion.